GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » EV-to-Revenue

AbCellera Biologics (STU:8QQ) EV-to-Revenue : 14.20 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AbCellera Biologics's enterprise value is €469.02 Mil. AbCellera Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €33.04 Mil. Therefore, AbCellera Biologics's EV-to-Revenue for today is 14.20.

The historical rank and industry rank for AbCellera Biologics's EV-to-Revenue or its related term are showing as below:

STU:8QQ' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.08   Med: 7.79   Max: 547.59
Current: 14.19

During the past 6 years, the highest EV-to-Revenue of AbCellera Biologics was 547.59. The lowest was 3.08. And the median was 7.79.

STU:8QQ's EV-to-Revenue is ranked worse than
61.66% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs STU:8QQ: 14.19

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), AbCellera Biologics's stock price is €3.554. AbCellera Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.11. Therefore, AbCellera Biologics's PS Ratio for today is 31.45.


AbCellera Biologics EV-to-Revenue Historical Data

The historical data trend for AbCellera Biologics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics EV-to-Revenue Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - 43.98 8.98 4.33 25.70

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.07 7.86 12.46 25.70 19.72

Competitive Comparison of AbCellera Biologics's EV-to-Revenue

For the Biotechnology subindustry, AbCellera Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's EV-to-Revenue falls into.



AbCellera Biologics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

AbCellera Biologics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=469.016/33.04
=14.20

AbCellera Biologics's current Enterprise Value is €469.02 Mil.
AbCellera Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (STU:8QQ) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

AbCellera Biologics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.554/0.113
=31.45

AbCellera Biologics's share price for today is €3.554.
AbCellera Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (STU:8QQ) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines